Status:
COMPLETED
Zevalin Post-marketing Surveillance in Japan
Lead Sponsor:
Spectrum Pharmaceuticals, Inc
Collaborating Sponsors:
Bayer
Conditions:
Non-Hodgkin's Lymphoma (NHL)
Eligibility:
All Genders
Brief Summary
This study is a regulatory post marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Zevalin for relapsed or refractory, CD20+, low grad...
Eligibility Criteria
Inclusion
- Patients who received Zevalin for relapsed or refractory:
- CD20+
- low grade B-cell non-Hodgkin's lymphoma
- Mantle cell lymphoma
Exclusion
- Patients who are contraindicated based on the product label
Key Trial Info
Start Date :
September 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 31 2018
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT01448928
Start Date
September 1 2008
End Date
January 31 2018
Last Update
October 1 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Multiple Locations, Japan